Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1T8D

Structure of the C-type lectin domain of CD23

Summary for 1T8D
Entry DOI10.2210/pdb1t8d/pdb
Related1t8c
DescriptorLow affinity immunoglobulin epsilon Fc receptor (1 entity in total)
Functional Keywordsc-type lectin, fcerii, fc receptor, ige, immune system
Biological sourceHomo sapiens (human)
Cellular locationCell membrane; Single-pass type II membrane protein: P06734
Total number of polymer chains1
Total formula weight16164.99
Authors
Hibbert, R.G.,Teriete, P.,Grundy, G.J.,Sutton, B.J.,Gould, H.J.,McDonnell, J.M. (deposition date: 2004-05-12, release date: 2005-07-26, Last modification date: 2024-10-30)
Primary citationHibbert, R.G.,Teriete, P.,Grundy, G.J.,Beavil, R.L.,Reljic, R.,Holers, V.M.,Hannan, J.P.,Sutton, B.J.,Gould, H.J.,McDonnell, J.M.
The structure of human CD23 and its interactions with IgE and CD21
J.Exp.Med., 202:751-760, 2005
Cited by
PubMed Abstract: The low-affinity immunoglobulin E (IgE) receptor, CD23 (FcepsilonRII), binds both IgE and CD21 and, through these interactions, regulates the synthesis of IgE, the antibody isotype that mediates the allergic response. We have determined the three-dimensional structure of the C-type lectin domain of CD23 in solution by nuclear magnetic resonance spectroscopy. An analysis of concentration-dependent chemical shift perturbations have allowed us to identify the residues engaged in self-association to the trimeric state, whereas ligand-induced changes have defined the binding sites for IgE and CD21. The results further reveal that CD23 can bind both ligands simultaneously. Despite the C-type lectin domain structure, none of the interactions require calcium. We also find that IgE and CD23 can interact to form high molecular mass multimeric complexes. The interactions that we have described provide a solution to the paradox that CD23 is involved in both up- and down-regulation of IgE and provide a structural basis for the development of inhibitors of allergic disease.
PubMed: 16172256
DOI: 10.1084/jem.20050811
PDB entries with the same primary citation
Experimental method
SOLUTION NMR
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon